Description

HBT1 Powder

Introduction

HBT1 Powder stands as an exclusive research product meticulously designed for scientific exploration, emphasizing its application in research and explicitly excluding any connection to human consumption. This powdered form of HBT1 offers researchers a versatile tool to investigate its potential benefits in the realms of neurotrophic factors and neurological diseases.

Key Characteristics

HBT1 exhibits unique pharmacological characteristics that make it a focus of neuroscientific research. Its properties may impact factors related to brain health and neurological function, prompting interest in its potential applications.

Research Applications

HBT1 Powder finds diverse applications in research domains, serving as a valuable tool for investigating its potential benefits, with a particular emphasis on brain-derived neurotrophic factor (BDNF) modulation and its impact on neurological diseases.

Research Benefits

HBT1 on Brain-derived Neurotrophic Factor (BDNF)

Studies suggest that HBT1 may influence the levels of Brain-derived Neurotrophic Factor (BDNF), a key neurotrophin associated with neuronal survival, growth, and differentiation. Exploring HBT1’s impact on BDNF levels provides valuable insights into its potential neuroprotective and neuroregenerative effects.

HBT1 on Neurological Diseases

Preliminary research indicates that HBT1 may have potential applications in addressing neurological diseases. Investigations into its impact on conditions such as neurodegenerative disorders could pave the way for therapeutic advancements.

Summary

HBT1 Powder, designed exclusively for research purposes, offers researchers a unique avenue for investigating its potential benefits on brain-derived neurotrophic factor (BDNF) modulation and its potential applications in addressing neurological diseases. The distinctive characteristics of HBT1 make it a promising subject for further exploration in neuroscientific research.

References

Kunugi, Akiyoshi & Tajima, Yasukazu & Kuno, Haruhiko & Sogabe, Satoshi & Kimura, Haruhide. (2018). HBT1, a Novel AMPA Receptor Potentiator with Lower Agonistic Effect, Avoided Bell-Shaped Response in In Vitro BDNF Production. Journal of Pharmacology and Experimental Therapeutics. 364. jpet.117.245050. 10.1124/jpet.117.245050. [Read More]

Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015 Dec 10;11(6):1164-78. doi: 10.5114/aoms.2015.56342. Epub 2015 Dec 11. PMID: 26788077; PMCID: PMC4697050. [Read More]